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Introduction
Botulism is an acute ﬂaccid paralysis caused by Clostrid-
ium botulinum neurotoxin. Botulism in humans is classiﬁed
into four forms: food borne, infant, wound and inhalation
botulism [1]. The former two are occasionally seen in
various parts of the world, whereas the latter two are
extremely rare. Inhalation botulism is attracting attention in
terms of its relevance to bioterrorism, although there has
been only one reported case of inhalation botulism that
occurred in a laboratory.
Etiology
Clostridia are anaerobic, obligate spore-forming, gram-
positive rods found widely in natural soils throughout the
world. Although C. botulinum spores are heat-resistant,
toxins are heat-labile and readily destroyed by heating at
85C or higher for 5 min. C. botulinum toxins block neu-
romuscular transmission irreversibly, causing airway or
respiratory muscle paralysis. Recovery from such paralysis
occurs when neurons are regenerated during the healing
process. C. botulinum toxins are classiﬁed into 7 types
(A to G) in terms of the antigenicity. Types A, B, E and F
cause botulism in humans [1].
Epidemiology
Food borne botulism
This form of botulism is caused by ingestion of food
containing C. botulinum toxin. Preserved foods including
home-canned foods, sausage and fermented ﬁsh such as
Izushi are common sources [2]. Therefore, reports of cases
are more frequent in temperate or cold zones, where food
preservation is a common practice. Botulism due to type E
toxin is predominant in Japan.
Infant botulism
This form of botulism is caused by toxins produced during
the process of budding and proliferation of ingested spores
in the intestine. This condition occurs in infants less than
1 year of age, and is particularly frequent 2–4 months after
birth. A survey carried out in Japan in 1986 revealed 10
patients, 30% of whom had been fed honey. The incidence
decreased sharply with a nationwide campaign designed to
discourage giving honey to infants. However, one case of
non-honey-related infant botulism is generally reported
every year. Although very rare, this condition may develop
in adults who have abnormal intestinal ﬂora resulting from
antibiotic therapy.
Wound botulism
This form of botulism is very rare; fewer than 300 cases
have been reported worldwide, to date. When wounded
skin is contaminated with C. botulinum spores, the spores
germinate, grow, and produce toxin in vivo, resulting in
clinical manifestations.
Clinical signs and symptoms
Neuroparalysis is characteristically symmetric, descending
and ﬂaccid, beginning with the cranial nerves. Consciousness
remains clear, and there are no abnormal sensations or fever.
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Food borne botulism
The following three major symptom types are character-
istically noted: ocular symptoms (amblyopia, blurred
vision, diplopia, strabismus, blepharoptosis, pupillary
dilatation, delayed light reﬂex), paralytic symptoms
(impaired speech, difﬁculty swallowing, tinnitus, hearing
loss, dyspnea, lack of facial expression, fatigability), and
impaired secretion (dry mouth). Symptoms depend on the
amount of toxin ingested.
Infant botulism
Usually, this condition is suspected with the presence of
constipation in infants who may also exhibit decreased
eating, somnolence, apathy and a weak cry). As paralysis
progresses, pharyngeal, sucking and corneal reﬂexes
decrease, eventually resulting in respiratory arrest. Abrupt
respiratory arrest sometimes occurs without prodromal
symptoms. Some proportion of sudden infant death syn-
drome cases are considered to be attributable to this disease.
Diagnosis
Botulism is suspected when the patient has an acute ﬂaccid,
symmetric, descending paralysis, but has clear conscious-
ness without accompanying fever or abnormal sensations.
Routine clinical laboratory tests yield normal results. A
deﬁnitive diagnosis is obtained when toxin in the serum is
identiﬁed, or when toxins or C. botulinum bacilli at the
wound site or in feces are identiﬁed in the presence of the
above paralytic symptoms. To identify the toxin, an intra-
peritoneal inoculation test in mice, ELISA, and the
reversed passive hemagglutination test are available. The
intraperitoneal inoculation test in mice is superior to other
tests in sensitivity. Isolation culture combined with the
PCR method or enrichment culture is used for identiﬁca-
tion of the bacillus.
Treatment
Elimination of the toxin from the gastrointestinal tract and
respiratory support until recovery, with nerve regeneration,
are the mainstays of treatment. Enemas are used to shorten
the intestinal retention time. Endotracheal intubation is
necessary in about half of all patients with infant botulism.
Nasogastric tube feeding and bladder catheterization are
used, as necessary [1, 2].
In patients with severe food borne botulism, equine anti-
toxin (univalent type E or polyvalent types A, B, E and F)
should be injected as early a stage as possible. Equine anti-
toxin is not used for infant botulism.
Antibiotics are not used to treat food borne or infant bot-
ulism because it is necessary to accelerate elimination of the
toxin. In cases of wound botulism, debridement of the wound
and administration of PCG, at 10,000,000–20,000,000
units/day (not based on sufﬁcient evidence), are carried out. If
complications such as pneumonia and urinary tract infection
occur during supportive care, antibiotics other than amino-
glycosides or tetracyclines, which can cause neuromuscular
blockade, are used.
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